Balanced Portfolio Recommendation: Buy – CSL Ltd (CSL)
CSL is also very close to trial results for a heart attack drug CSL112, a key pipeline product for CSL. Base case assumptions imply a valuation of around $30/share.
csl
Pre-Market Pulse 15th August – Equities end higher as investors buy dip in tech
Weakness in banks was offset by renewed demand for tech amid a surge in Nvidia ahead of a slew of incoming economic data set to provide further insight on the consumer.